Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference

GlobeNewsWire
Monday, November 20, 2023 at 9:05pm UTC

CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the 35th Annual Piper Sandler Healthcare Conference to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Brett Hall, Ph.D., Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.

Format: Fireside chat and 1x1 Investor Meetings
Presentation: November 30, 2023 from 11:30 – 11:55 am ET

The presentations will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

About Immuneering Corporation

Immuneering is a clinical-stage oncology company seeking to develop medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The Company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. The company’s development pipeline also includes IMM-6-415, a universal-MAPK program, as well as several early-stage programs. For more information, please visit www.immuneering.com.

Media Contact:
Gina Nugent 
Nugent Communications 
617-460-3579 
gina@nugentcommunications.com 

Investor Contacts: 
Laurence Watts 
Gilmartin Group 
619-916-7620 
laurence@gilmartinir.com 

or

Kiki Patel, PharmD 
Gilmartin Group 
332-895-3225
kiki@gilmartinir.com 


Primary Logo